Aug 2026· Neurology, neuropsychiatry, Psychosomatics· Vol 18, pp. 122-127· 0 citations· 21 references
TL;DR
A personalized approach to the treatment of generalized myasthenia gravis should take into account serological status, disease activity, the frequency of exacerbations, comorbidities, tolerance to treatment, the possibility of reducing the dose of glucocorticoids, and the patient's preferences.
Abstract
Generalized myasthenia gravis is a chronic autoimmune disorder characterized by an attack on the structures of the neuromuscular junction and by fluctuating muscle weakness and pathological fatigue, involving the ocular, bulbar, respiratory and skeletal muscles. Modern treatment of generalized myasthenia gravis aims to achieve sustained control of the disease, reduce the risk of exacerbations and myasthenic crises, and maintain the patient's quality of life. Some patients continue to experience a significant burden of disease, reduced daily activity, a need for longterm immunosuppressive therapy, and a risk of developing adverse events. A personalized approach to the treatment of generalized myasthenia gravis should take into account serological status, disease activity, the frequency of exacerbations, comorbidities, tolerance to treatment, the possibility of reducing the dose of glucocorticoids, and the patient's preferences.
Myasthenia gravis (MG) is a rare autoimmune disorder caused by autoantibodies targeting postsynaptic proteins of the neuromuscular junction. Although conventional therapies can achieve remission or sufficient symptom control in most patients with generalized MG (gMG), approximately 10%-30% of patients remain treatment...
Hebatallah R. Rashed· Muscle and Nerve· 0 citations
The pathogenesis of MG is reviewed, the current applications of conventional drugs, targeted biologics, thymectomy, and gene therapy in its treatment are outlined, existing therapeutic challenges are analyzed, and future directions, such as precision medicine and novel targeted therapies are explored.
Jia-Qi Lin· International Journal of Pub...· 0 citations
BACKGROUND AND OBJECTIVES
Generalized myasthenia gravis (gMG) is a chronic fluctuating neuromuscular disease. Some patients keep experiencing symptoms or adverse events (AEs) despite tailored therapeutic schemes. The aim of this study was to characterize adequately controlled gMG and describe patients' evolution and ou...
D. Reyes-Leiva, Á. Carbayo, A. Vesperinas et al.· Neurology· 0 citations
INTRODUCTION
Conventional treatments for generalized myasthenia gravis (gMG) include acetylcholinesterase inhibitors (AChEi), systemic corticosteroids, and non-steroidal immunosuppressants; standard of care for exacerbation or myasthenic crisis includes immunoglobulin and plasmapheresis; newer advanced treatments inclu...
Kavita Grover, Martin Cloutier, G. Coteur et al.· Neurological Therapeutics· 0 citations
Myasthenia gravis (MG) is a chronic autoimmune disease characterized by fluctuating skeletal muscle weakness resulting from impaired neuromuscular transmission, most commonly caused by autoantibodies against acetylcholine receptors (AChR). Immunosuppressive therapy remains the cornerstone of long-term disease managemen...
Handy Rifaldi, S. Sutarni, Indra Sari Kusuma Harahap et al.· Berkala NeuroSains· 0 citations
Graves’ orbitopathy (GO), also referred to as thyroid eye disease (TED) or endocrine orbitopathy (EO), is the most common extrathyroidal manifestation of Graves’ disease, affecting approximately 25–40% of patients. The pathogenesis of GO is complex and multifactorial, primarily involving autoimmune processes driven by...
Damian Świerczek, A. Piwko, Szymon Starowicz et al.· International Journal of Inn...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
